We’ve recently updated our valuation analysis.

PetIQ Valuation

Is PETQ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PETQ?

Other financial metrics that can be useful for relative valuation.

PETQ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.8x
Enterprise Value/EBITDA13.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PETQ's PS Ratio compare to its peers?

The above table shows the PS ratio for PETQ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average0.6x
OMI Owens & Minor
0.2x3.6%US$1.5b
GEG Great Elm Group
0.9xn/aUS$60.9m
PDCO Patterson Companies
0.4x3.1%US$2.8b
AHCO AdaptHealth
1x10.6%US$2.9b
PETQ PetIQ
0.4x6.7%US$337.1m

Price-To-Sales vs Peers: PETQ is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (0.6x).


Price to Earnings Ratio vs Industry

How does PETQ's PE Ratio compare vs other companies in the US Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.4%
n/an/an/a

Price-To-Sales vs Industry: PETQ is good value based on its Price-To-Sales Ratio (0.4x) compared to the US Healthcare industry average (1x)


Price to Sales Ratio vs Fair Ratio

What is PETQ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PETQ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.4x
Fair PS Ratio0.6x

Price-To-Sales vs Fair Ratio: PETQ is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).


Share Price vs Fair Value

What is the Fair Price of PETQ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PETQ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PETQ's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PETQ forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$11.54
US$24.25
+110.1%
24.8%US$30.00US$16.00n/a4
Nov ’23US$8.20
US$24.25
+195.7%
24.8%US$30.00US$16.00n/a4
Oct ’23US$6.90
US$25.50
+269.6%
17.6%US$30.00US$21.00n/a4
Sep ’23US$9.03
US$27.25
+201.8%
13.6%US$30.00US$21.00n/a4
Aug ’23US$16.82
US$30.75
+82.8%
6.2%US$34.00US$29.00n/a4
Jul ’23US$17.71
US$30.75
+73.6%
6.2%US$34.00US$29.00n/a4
Jun ’23US$16.31
US$30.75
+88.5%
6.2%US$34.00US$29.00n/a4
May ’23US$19.90
US$34.60
+73.9%
22.8%US$50.00US$29.00n/a5
Apr ’23US$25.00
US$34.50
+38.0%
20.9%US$50.00US$29.00n/a6
Mar ’23US$18.31
US$35.83
+95.7%
18.3%US$50.00US$30.00n/a6
Feb ’23US$20.32
US$35.83
+76.3%
18.3%US$50.00US$30.00n/a6
Jan ’23US$22.71
US$35.83
+57.8%
18.3%US$50.00US$30.00n/a6
Dec ’22US$20.12
US$35.83
+78.1%
18.3%US$50.00US$30.00n/a6
Nov ’22US$25.83
US$41.00
+58.7%
13.1%US$50.00US$34.00US$8.206
Oct ’22US$25.50
US$42.40
+66.3%
11.2%US$50.00US$36.00US$6.905
Sep ’22US$26.55
US$43.20
+62.7%
9.0%US$50.00US$40.00US$9.035
Aug ’22US$35.36
US$49.80
+40.8%
5.7%US$54.00US$45.00US$16.825
Jul ’22US$38.26
US$49.80
+30.2%
5.7%US$54.00US$45.00US$17.715
Jun ’22US$37.63
US$49.80
+32.3%
5.7%US$54.00US$45.00US$16.315
May ’22US$42.60
US$46.60
+9.4%
6.2%US$50.00US$43.00US$19.905
Apr ’22US$35.38
US$44.80
+26.6%
6.7%US$50.00US$41.00US$25.005
Mar ’22US$35.66
US$44.60
+25.1%
7.3%US$50.00US$40.00US$18.315
Feb ’22US$34.28
US$41.60
+21.4%
12.8%US$50.00US$35.00US$20.325
Jan ’22US$38.45
US$40.60
+5.6%
14.7%US$50.00US$35.00US$22.715
Dec ’21US$29.06
US$40.60
+39.7%
14.7%US$50.00US$35.00US$20.125
Nov ’21US$28.56
US$44.40
+55.5%
6.9%US$50.00US$41.00US$25.835

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies